Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice

A Bai, E Higham, HN Eisen… - Proceedings of the …, 2008 - National Acad Sciences
A Bai, E Higham, HN Eisen, KD Wittrup, J Chen
Proceedings of the National Academy of Sciences, 2008National Acad Sciences
To study T cell responses to tumors in an autochthonous model, we expressed a CD8 T cell
epitope SIYRYYGL (SIY) in the prostate of transgenic adenocarcinoma (TRAMP) mice
(referred to as TRP-SIY), which spontaneously develop prostate cancer. Naïve SIY-specific
CD8 T cells adoptively transferred into TRP-SIY mice became tolerized in the prostate
draining lymph nodes. Vaccination of TRP-SIY mice intranasally with influenza virus that
expresses the SIY epitope resulted in generation of SIY-specific effector T cells in the lung …
To study T cell responses to tumors in an autochthonous model, we expressed a CD8 T cell epitope SIYRYYGL (SIY) in the prostate of transgenic adenocarcinoma (TRAMP) mice (referred to as TRP-SIY), which spontaneously develop prostate cancer. Naïve SIY-specific CD8 T cells adoptively transferred into TRP-SIY mice became tolerized in the prostate draining lymph nodes. Vaccination of TRP-SIY mice intranasally with influenza virus that expresses the SIY epitope resulted in generation of SIY-specific effector T cells in the lung-draining lymph nodes. These effector T cells expressed TNFα and IFNγ, eliminated SIY peptide-loaded target cells in vivo, and infiltrated prostate tumors, where they rapidly lost the ability to produce effector cytokines. A population of these T cells persisted in prostate tumors but not in lymphoid organs and could be induced to re-express effector functions following cytokine treatment in vitro. These findings suggest that T cells of a given clone can be activated and tolerized simultaneously in different microenvironments of the same host and that effector T cells are rapidly tolerized in the tumors. Our model provides a system to study T cell-tumor interactions in detail and to test the efficacy of cancer immunotherapeutic strategies.
National Acad Sciences